HC Wainwright Estimates Dare Bioscience Q1 Earnings

Dare Bioscience, Inc. (NASDAQ:DARE) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Dare Bioscience in a report issued on Friday, August 14th. HC Wainwright analyst D. Tsao expects that the biotechnology company will earn ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.05) EPS and FY2030 earnings at $6.27 EPS.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.00 million.

A number of other equities research analysts have also issued reports on DARE. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Friday, July 17th. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a research note on Monday. Finally, Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Dare Bioscience Stock Performance

Dare Bioscience stock opened at $0.81 on Monday. The firm has a market cap of $12.22 million, a PE ratio of -1.16 and a beta of 1.08. The firm’s 50 day moving average price is $1.72 and its two-hundred day moving average price is $1.87. Dare Bioscience has a twelve month low of $0.77 and a twelve month high of $3.78.

Hedge Funds Weigh In On Dare Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in Dare Bioscience in the third quarter worth approximately $37,000. Raymond James Financial Inc. increased its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares during the last quarter. Finally, LPL Financial LLC bought a new position in shares of Dare Bioscience during the 4th quarter valued at $28,000. Institutional investors own 6.70% of the company’s stock.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.